Indeed, the capacity to mount a strong anti-tumor response is likely to be influenced by the characteristics of the patient such as immunosenescence but also the characteristics of the tumor given that tumor mutational burden is a strong predictor of the effectiveness of anti-PD1/PD-L1 treatment (118, 119). Here, CD274 is linked to neoplasm.